Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06022328
Recruiting Observational

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)

NCT06022328 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Bordeaux
Phase
Observational
Started
2023-12-15
Last updated
2025-07-30

Condition(s) studied

Myeloproliferative Neoplasm

Investigational drug(s) / intervention(s)

Assessment of the epigenetic age

Assessment of the epigenetic age: Retrospective assessment of the epigenetic age on DNA samples obtained at diagnosis

Study summary

Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive diseases (myelofibrosis and acute leukemia). Aging remains the principal factor determining patients' survival in MPN. In recent years, DNA methylation has appeared as a mean to measure aging via the development of epigenetic clocks that have also been associated with the occurrence of thrombosis and cancer. The epiC project aims at determining epigenetic age of MPN patients and search for an association between this parameter and thrombotic/hematological complications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: For the 110 patients with MPN: * Patients with PV, ET or PMF * DNA extracted from purified granulocytes at time of diagnosis * No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) For the 10 subjects without MPN: * Absence of hematological malignancy * Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia * Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) Exclusion Criteria: For the 110 patients with MPN: * Patients without PV, ET or PMF * Patients without purified granulocytes DNA available at time of diagnosis * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling * Patients with less than 2 years' follow-up For the 10 subjects in NMP : * Patients with hematological malignancy and/or solid cancer * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling

Primary outcome measure(s)

  • Accelerated ageing of patients — At inclusion, up to 1 year after diagnosis
    Accelerated ageing will be defined as an increased difference between the epigenetic age (calculated from DNA methylation data with the different molecular clocks described: DNAmAge, DNAmHannum, DNAmPhenoAge, DNAmSkinClock, DNAmGrimAge, intrinsic epigenetic age acceleration, extrinsic epigenetic age acceleration) and the chronological age

Trial sites (1)

FacilityCityRegionStatus
CHU de Bordeaux, service Hématologie Biologique Bordeaux France Recruiting

More University Hospital, Bordeaux trials in France

Validation of a Digitalised Intraoral Protection Recruiting
Mitochondrial Disease-associated ImmunoDeficiencies Recruiting
ESCAPE : Evaluation of Spinal Conservation by Endoscopic Procedures to Avoid Fusion Recruiting
Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre Recruiting
COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial Recruiting

Other trials for the same condition

Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM) Recruiting
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. Recruiting
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms Recruiting
Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06022328 on ClinicalTrials.gov ↗ ← All trials in France